Onconetix, Inc. - Multiplikator Forward P/S ONCO
Onconetix, Inc. focuses on developing advanced diagnostic systems and pharmaceuticals for the therapy of urological tumors. The forward P/S indicator visualizes market expectations, where 1.90 serves as the base value of the parameter. The brand's ecosystem integrates biotechnology with telemedicine for men's health, while optimized raw material supply chains ensure stable procurement without logistical disruptions.
ONCO (Onconetix): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- rincian nilai pasar emiten:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Onconetix, Inc.|ONCO - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Onconetix, Inc.|ONCO - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Onconetix Corp|ONCO - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Onconetix|Indikator likuiditas cepet onconetix.gcs-web.com
- data bathi bisnis lan rasio investasi:
ONCO - Bathi pungkasan|Proyeksi bathi mangsa ngarep Onconetix, Inc.|ONCO - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Onconetix|ONCO - Rasio P/E diaturake wutah|Pangali EV/EBITDA Onconetix Inc|ONCO - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Onconetix|ONCO - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan onconetix.gcs-web.com|ONCO - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Onconetix, Inc.
- rincian pendapatan lan dodolan:
Analisis umum perusahaan:Onconetix Corporation ONCO
Driven by patent protection and the scalability of its oncology drugs, Onconetix, Inc. (ONCO) is capable of increasing revenue without a proportional rise in costs, which is reflected in the trend of the expected P/S ratio. This indicator correlates market capitalization with projected sales, allowing investors to determine the extent of the premium paid for future growth and identify the boundaries of a fair business valuation during periods of expansion.
Analisis perusahaan pesaing
Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS - Multiplikator Forward P/S|RVTY (Revvity) - Multiplikator forward rega marang pendapatan|Bio-Rad - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan anbio.com|Multiplikator Forward P/S Sotera Health Company|Rasio rega marang prakiraan pendapatan QuidelOrtho (QDEL)|OPK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|caredx.com - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Maravai LifeSciences Corp (MRVI)|FLGT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Rasio rega marang prakiraan pendapatan|OSUR: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan XGN|MDXH: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lucid Diagnostics Inc. (LUCD)|Rasio rega marang prakiraan pendapatan PRE (Prenetics Global Limited)|Multiplikator Forward P/S IMDX (Insight Molecular Diagnostics Inc)|Rasio rega marang pendapatan sing dikarepake TRIB (Trinity Biotech Corp)|PRPH - Rasio rega marang prakiraan pendapatan|Ainos (AIMD) - Multiplikator forward rega marang pendapatan|CoDx (CODX) - Rasio rega marang prakiraan pendapatan|HSCS (Heart Test Labs) - Rasio rega marang prakiraan pendapatan|BMRA (Biomerica, Inc.) - Multiplikator Forward P/S|CDIO (Cardio Diagnostics) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Virax Biolabs (VRAX)|Rasio rega marang pendapatan sing dikarepake BJDX|Rasio rega marang prakiraan pendapatan Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc
